| 摘要 |
The present invention relates to a method for the use of a bradykinin B1 receptor antagonist of formula I: <?in-line-formulae description="In-line Formulae" end="lead"?>X-CO-Aaa<SUB>0</SUB>-Aaa<SUB>1</SUB>-Aaa<SUB>2</SUB>-Aaa<SUB>3</SUB>-Gly-alpha(Me)Phe-Ser-D-betaNal-Aaa<SUB>8</SUB>-OH (I)<?in-line-formulae description="In-line Formulae" end="tail"?> or a pharmaceutically acceptable salt or hydrate thereof wherein: X is C<SUB>n</SUB>H<SUB>2n+1 </SUB>or C<SUB>i</SUB>H<SUB>2i</SUB>-C<SUB>6</SUB>H<SUB>5</SUB>, where n is an integer from 1 to 3, and i is an integer from 0 to 3; Aaa<SUB>0 </SUB>is Lys, Orn or Cit; Aaa<SUB>1 </SUB>is Arg or Cit, and preferably Arg; Aaa<SUB>2 </SUB>is Oic, Hyp or Pro, and preferably Oic; Aaa<SUB>3 </SUB>is Pro or Oic, and preferably Pro; and Aaa<SUB>8 </SUB>is Ile, Leu, Nle, and preferably Ile, for the treatment of metastases, cancers and/or chemotherapy-induced neuropathies, comprising the administration of said compound to a patient in need of such treatment. The present invention also relates to compositions containing such antagonists and the uses thereof.
|
